European Urology Oncology

Slides:

Advertisements

Similar presentations

Volume 165, Issue 5, Pages (May 2001)

Advertisements

Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors1 Gottfrid.

Volume 105, Issue 3, Pages (March 1994)

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Volume 58, Issue 2, Pages (August 2010)

Volume 58, Issue 5, Pages (November 2010)

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Volume 70, Issue 6, Pages (December 2016)

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Volume 67, Issue 4, Pages (April 2015)

European Urology Oncology

European Urology Oncology

Volume 52, Issue 3, Pages (September 2007)

European Urology Oncology

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Volume 63, Issue 1, Pages (January 2013)

European Urology Oncology

Volume 55, Issue 6, Pages (June 2009)

Volume 73, Issue 2, Pages (February 2018)

European Urology Oncology

European Urology Oncology

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 61, Issue 6, Pages (June 2012)

Volume 63, Issue 3, Pages (March 2013)

Volume 43, Issue 2, Pages (February 2003)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Volume 53, Issue 1, Pages (January 2008)

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Periodic pharyngolaryngoscopy detects early head and neck cancer and improves survival in esophageal cancer Akihito Watanabe, MD, Masao Hosokawa, MD,

European Urology Oncology

Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung Cancer Katsuhiko Matsuyama, Yukio Chiba, Masato Sasaki, Hirokazu Tanaka, Ryusuke.

European Urology Oncology

European Urology Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Volume 122, Issue 1, Pages (January 2002)

Katja Lundgren, Nicholas P

Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma Masahiro Yasunaga,

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Deregulated p21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Yih-Gang Goan, MD, Hon-Ki Hsu,

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

European Urology Oncology

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Volume 151, Issue 1, Pages (October 2018)

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Development and Validation of an Improved Pathological Nodal Staging System for Urothelial Carcinoma of the Bladder Devin N. Patel, Michael Luu, Zachary.

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

European Urology Oncology

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

It’s All in the “Swerve of the Curve”

European Urology Oncology

European Urology Oncology

Jan Roigas European Urology Supplements

Neal S Goldstein, MD The Annals of Thoracic Surgery

European Urology Oncology

European Urology Oncology

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

European Urology Oncology

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

European Urology Oncology PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes Sabina Davidsson, Jessica Carlsson, Francesca Giunchi, Alyssa Harlow, Peter Kirrander, Jennifer Rider, Michelangelo Fiorentino, Ove Andrén European Urology Oncology DOI: 10.1016/j.euo.2018.07.010 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 PD-L1 protein expression in tumor cells and tumor-infiltrating immune (TII) cells in penile squamous cell carcinoma specimens (brown chromogen). PD-L1 positivity in (A) tumor cells and (B) TII cells detected with anti-PD-L1 antibody clone SP142. (C) PD-L1 positivity in (C) tumor cells and (D) TII cells detected with anti-PD-L1 antibody clone 28.8. Magnification 10× for all images. European Urology Oncology DOI: (10.1016/j.euo.2018.07.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier curve showing that patients with penile squamous cell carcinoma with PD-L1 expression in tumor cells, detected with anti-PD-L1 antibody clone SP142, have shorter cancer-specific survival than patients without PD-L1 expression in tumor cells. Product-limit survival estimates with 95% Hall-Wellner and equal precision bands. European Urology Oncology DOI: (10.1016/j.euo.2018.07.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier curve showing that patients with penile squamous cell carcinoma with PD-L1 expression in tumor cells, detected with anti-PD-L1 antibody clone 28.8, have shorter cancer-specific survival than patients without PD-L1 expression in tumor cells. Product-limit survival estimates with 95% Hall-Wellner and equal precision bands. European Urology Oncology DOI: (10.1016/j.euo.2018.07.010) Copyright © 2018 European Association of Urology Terms and Conditions